The detection of specific mutations in genes such as PTEN, PIK3R1, CTCF, and BRAF, which correlate with advanced disease features like high-grade tumors and deep myometrial infiltration, suggests that cfDNA analysis could become a crucial tool in the clinical management of endometrial cancer. The gene discussed is BRAF; the disease is endometrial cancer.